Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution (NYSE:EBS)
· seekingalpha.com
Emergent BioSolutions faces margin pressure, lowered FY26 guidance, and weak profitability despite cost cuts. Learn more about EBS stock here.
The big message we got from the Emergent BioSolutions Inc. ( EBS ) call is that whilst they're making some tangible progress on the balance sheet and cost struc...